Wealth Effects LLC Decreases Stock Position in Zoetis Inc. $ZTS

Wealth Effects LLC cut its holdings in Zoetis Inc. (NYSE:ZTS) by 12.0% in the second quarter, HoldingsChannel reports. The firm owned 1,467 shares of the company’s stock after selling 200 shares during the quarter. Wealth Effects LLC’s holdings in Zoetis were worth $229,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Portside Wealth Group LLC boosted its stake in shares of Zoetis by 24.7% during the first quarter. Portside Wealth Group LLC now owns 33,709 shares of the company’s stock valued at $5,550,000 after purchasing an additional 6,672 shares during the period. Tandem Investment Advisors Inc. lifted its holdings in Zoetis by 100.3% during the first quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company’s stock worth $65,140,000 after buying an additional 198,089 shares during the period. Flagship Harbor Advisors LLC boosted its position in Zoetis by 31.2% during the first quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company’s stock valued at $1,217,000 after purchasing an additional 1,760 shares in the last quarter. Horizon Financial Services LLC purchased a new position in shares of Zoetis in the 1st quarter worth approximately $380,000. Finally, Soros Capital Management LLC increased its position in shares of Zoetis by 32.0% during the first quarter. Soros Capital Management LLC now owns 17,441 shares of the company’s stock worth $2,872,000 after purchasing an additional 4,230 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Price Performance

ZTS stock opened at $141.65 on Thursday. Zoetis Inc. has a 1 year low of $139.70 and a 1 year high of $197.51. The business’s 50-day moving average is $150.63 and its two-hundred day moving average is $156.07. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The firm has a market capitalization of $62.78 billion, a P/E ratio of 24.38, a P/E/G ratio of 2.29 and a beta of 0.89.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. During the same period in the previous year, the business earned $1.56 EPS. Zoetis’s revenue for the quarter was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ZTS has been the subject of several research reports. Stifel Nicolaus downgraded shares of Zoetis from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Leerink Partners downgraded shares of Zoetis from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Argus restated a “buy” rating and issued a $190.00 price objective on shares of Zoetis in a research report on Tuesday, September 9th. Piper Sandler increased their target price on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Finally, Leerink Partnrs lowered shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Five research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $200.88.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.